UMeWorld Releases Clinical Results: DAG Oil Shows Significant Reductions in Uric Acid, Cholesterol, Triglycerides, and Weight
MWN-AI** Summary
UMeWorld Limited (OTC: UMEWF) announced promising results from a clinical study focusing on their product, DAG oil, which is the key ingredient in their cooking oil brand, DAGola. Conducted with 820 overweight participants aged 18 to 75, the study examined the effects of DAG oil on metabolic health by monitoring changes in health markers including uric acid, cholesterol, triglycerides, and weight. Participants consumed DAG oil exclusively in their home-cooked meals for two months, which restricted dining out to maintain control over dietary intake.
A total of 415 participants completed the study, revealing significant health improvements. After one month, there were reductions in uric acid and cholesterol levels, while after two months, weight, body mass index (BMI), and triglycerides also significantly decreased. These findings highlight DAG oil's potential role in improving metabolic health, particularly for individuals at risk for conditions such as diabetes and cardiovascular disease.
According to UMeWorld's CEO Michael Lee, the clinical validation of DAGola aligns with their mission to provide consumers healthier cooking alternatives without sacrificing taste. The company offers four variants of DAG-based oils, each designed for culinary excellence and metabolic support, promising up to 50% fewer triglycerides than standard oils.
UMeWorld is positioning DAGola not just as a cooking oil but as a functional nutrition solution that can have real health benefits. The study's results underline the importance of dietary choices in managing metabolic diseases and affirm UMeWorld's commitment to innovation in the cooking oil industry, aiming for solutions that integrate health into daily nutrition.
MWN-AI** Analysis
UMeWorld Limited (OTC: UMEWF) recently announced compelling clinical results for its product, DAGola, demonstrating significant health benefits that position it favorably in the health-conscious cooking oil market. The study showed that consumption of DAG oil resulted in substantial reductions in uric acid, cholesterol, triglycerides, and body weight among participants, which is significant given the rising prevalence of metabolic diseases worldwide. This data provides a robust foundation for marketing DAGola as not just a cooking oil but as a health-enhancing functional food.
From an investment standpoint, UMeWorld's stock could warrant attention due to the increasing consumer interest in health and wellness products. As evidenced by the study, DAGola's clinically backed attributes may appeal to a broader audience seeking alternatives to traditional cooking oils, especially those particularly health-focused. The company’s innovative approach also addresses growing trends in preventive healthcare, potentially leading to greater market penetration.
However, investors should be cautious given the reported high dropout rates in the clinical trial, indicating that adherence to dietary changes can be challenging. This insight may reflect broader challenges in the functional foods market, where consumer behavior can vary widely.
Moving forward, UMeWorld’s strategy should involve compelling marketing that emphasizes the scientific underpinnings of DAGola, making it clear how the product can seamlessly integrate into everyday diets without compromising flavor or health. The company could stand to benefit from partnerships with health professionals to endorse its products, thus enhancing credibility.
In conclusion, UMeWorld Limited presents a promising investment opportunity if it successfully capitalizes on the clinical study results and addresses consumer adherence challenges, positioning DAGola as a leader in the functional cooking oil segment. Traders should monitor UMEWF's market performance, news developments, and consumer reception to gauge its future momentum.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) today announced the results of a clinical study demonstrating the metabolic benefits of diacylglycerol (DAG) oil, the active ingredient in its functional cooking oil brand, DAGola. The study confirmed that regular consumption of DAG oil led to significant improvements in key health markers, including uric acid, triglycerides, cholesterol, and body weight.
The study, titled “The study on the effects of diacylglycerol (DAG) oil in patients with elevated blood glucose levels and overweight”, was conducted with 820 adult participants aged 18 to 75 who were overweight (BMI > 24.0 kg/m²) and had either glycated hemoglobin (HbA1c) levels ? 5.7% or fasting blood glucose ? 5.6 mmol/L. Participants agreed to adopt a structured dietary intervention that included exclusive use of DAG oil in home-cooked meals. Dining out was prohibited during the study period in order to tightly control dietary intake.
A total of 415 participants completed the two-month program. The dropout rate was higher than anticipated, largely due to difficulty adhering to the no–dining out requirement, highlighting the role of eating habits in long-term nutritional interventions.
Clinical results were analyzed using the paired-sample T-test method. After one month of DAG oil consumption, participants with elevated levels saw significant reductions in uric acid (P < 0.01), total cholesterol (P < 0.01), and LDL-C (P < 0.05). After two months, weight and BMI dropped significantly (P < 0.01), uric acid remained significantly reduced (P < 0.01), and triglyceride levels showed a marked decrease (P < 0.001).
These results suggest that DAG oil can contribute meaningfully to improving metabolic balance, particularly in populations at risk for hyperuricemia, dyslipidemia, obesity, and early-stage insulin resistance. The findings position DAGola not only as a premium culinary oil, but as a functional nutrition solution backed by clinical evidence.
Metabolic disease affects hundreds of millions of people worldwide. Often rooted in diet and lifestyle, conditions like type 2 diabetes, obesity, and cardiovascular disease are largely preventable - and in many cases, reversible. Functional foods like DAGola offer a practical, everyday way to help individuals take control of their health, starting in their own kitchens.
“This study validates the science behind DAGola,” said Michael Lee, CEO of UMeWorld. “For too long, consumers have had to choose between flavor, convenience, and genuine health benefits. We believe it’s time for that to change. Our mission with DAGola is to make advanced nutrition effortless - by putting clinically supported, high-performance oils in kitchens everywhere. DAGola isn’t just another cooking oil; it’s a daily upgrade to metabolic wellness, backed by real science and crafted with care. We’re proud to offer a product that delivers measurable benefits in everyday use - without compromising on taste or quality.”
DAGola offers 4 high-performance DAG-based oils: Gourmet Blend, Vitality Blend, Master Chef Blend and Premium Blend. Each is crafted for culinary excellence and metabolic support, with select blends delivering up to 50% fewer triglycerides than conventional oils. While small amounts of DAG occur naturally in oils like olive oil - typically less than 3% - DAGola products are specially formulated using a proprietary enzymatic technology to provide a significantly higher DAG content for enhanced wellness benefits. Available online at www.cellugizer.com or amazon.com/dagola.
About UMeWorld
UMeWorld is redefining the cooking oil industry through science and innovation. Our flagship product, DAGola™, contains up to 50% less triglycerides than traditional oils and is clinically proven in multiple human trials to support heart health and improve lipid metabolism. Using a proprietary enzymatic technology, we produce functional oils that help combat metabolic syndrome, which affects over 47 million Americans. This same advanced process also converts palm and used cooking oils into eco-friendly biofuels. Our mission is to lead in next-generation nutrition and sustainable energy, delivering innovation with real-world impact.
About DAGola Inc.
DAGola Inc. is the U.S. branch of UMeWorld Limited. It focuses on selling innovative food products in North America. To learn more about DAGola Inc., visit www.dagolaoil.com .
Forward-Looking Statements
This press release may contain forward-looking statements, about UMeWorld's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, UMeWorld or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by UMeWorld with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of UMeWorld's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause UMeWorld's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause UMeWorld's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in UMeWorld's filings with the SEC. In addition, UMeWorld operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. UMeWorld does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors associated with an investment in our securities which are included in our Annual Report on Form 20-F and other periodic and current reports filed with the Securities and Exchange Commission.
Contact:Michael LeeUMeWorld LimitedEmail: info@umeworld.com
FAQ**
What specific measures is UMeWorld Ltd UMEWF taking to ensure long-term adherence to dietary interventions like those required in the clinical study on DAG oil, given the reported higher dropout rates?
How does UMeWorld Ltd UMEWF plan to leverage the clinical study's findings to increase market penetration for DAGola, particularly among consumers focusing on metabolic health?
What competitive advantages does UMeWorld Ltd UMEWF believe DAGola has over traditional cooking oils, and how does it plan to communicate these benefits to potential customers?
Are there any plans from UMeWorld Ltd UMEWF to expand its product line of DAG-based oils beyond the current four blends, based on the study's positive health outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about UMeWorld Ltd (OTC: UMEWF).
NASDAQ: UMEWF
UMEWF Trading
41900.0% G/L:
$0.42 Last:
1,000 Volume:
$0.42 Open:
